ImmVirx Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $16.6M

  • Investors
  • 4

ImmVirx General Information

Description

Developer of novel oncolytic immunotherapies designed to target cancer indications with unmet needs. The company harnesses the power of bio-selected RNA viruses to preferentially infect and kill cancer cells, inudcing systemic anti-tumor immune responses against cancer cells to increase the effectiveness of current immunotherapies, primarily immune checkpoint inhibitors and CAR-T cell therapies, enabling doctors to treat cancer and improve outcomes for patients with cancer.

Contact Information

Website
www.immvirx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Level 2, HMRI Building
  • 1 Kookaburra Cct
  • New Lambton Heights, New South Wales 2305
  • Australia
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Level 2, HMRI Building
  • 1 Kookaburra Cct
  • New Lambton Heights, New South Wales 2305
  • Australia

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmVirx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 05-Jun-2023 $16.6M Completed Pre-Clinical Trials
2. Early Stage VC (Series A1) 07-Apr-2021 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 13-Jan-2020 $2.08M $2.08M Completed Startup
To view ImmVirx’s complete valuation and funding history, request access »

ImmVirx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B Preference Shares
Series A1
Series A 3,000,000 $0.66 $0.66 1x $0.66 13.75%
To view ImmVirx’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

ImmVirx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel oncolytic immunotherapies designed to target cancer indications with unmet needs. The company harness
Drug Discovery
New Lambton Heights, Australia
24 As of 2025

Helsinki, Finland
 

Sydney, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmVirx Competitors (3)

One of ImmVirx’s 3 competitors is Valo Therapeutics, a Venture Capital-Backed company based in Helsinki, Finland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Valo Therapeutics Venture Capital-Backed Helsinki, Finland
Imugene Corporation Sydney, Australia
Atara Biotherapeutics Formerly VC-backed Thousand Oaks, CA
You’re viewing 3 of 3 competitors. Get the full list »

ImmVirx Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 8

    Pending

  • Expiring in next 12 mo

ImmVirx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2026901077-A0 Oncolytic viruses as therapeutic agents for treating cancer Pending 10-Feb-2026
AU-2025900811-A0 Oncolytic viruses as therapeutic agents for treating cancer Pending 14-Mar-2025
AU-2023900305-A0 Oncolytic viruses as therapeutic agents for treating cancer Pending 08-Feb-2023
AU-2023900306-A0 Oncolytic viruses as therapeutic agents for treating cancer Pending 08-Feb-2023
AU-2024218405-A1 Oncolytic viruses as therapeutic agents for treating cancer Pending 08-Feb-2023 C12N7/00
To view ImmVirx’s complete patent history, request access »

ImmVirx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmVirx Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
OneVentures Venture Capital Minority
Wunala Capital Growth/Expansion Minority
Acorn Capital Growth/Expansion Minority
Boman Group Venture Capital Minority
To view ImmVirx’s complete investors history, request access »

Ready to get started?

Request a free trial

ImmVirx FAQs

  • When was ImmVirx founded?

    ImmVirx was founded in 2019.

  • Where is ImmVirx headquartered?

    ImmVirx is headquartered in New Lambton Heights, Australia.

  • What is the size of ImmVirx?

    ImmVirx has 24 total employees.

  • What industry is ImmVirx in?

    ImmVirx’s primary industry is Drug Discovery.

  • Is ImmVirx a private or public company?

    ImmVirx is a Private company.

  • What is the current valuation of ImmVirx?

    The current valuation of ImmVirx is .

  • What is ImmVirx’s current revenue?

    The current revenue for ImmVirx is .

  • How much funding has ImmVirx raised over time?

    ImmVirx has raised $37.8M.

  • Who are ImmVirx’s investors?

    OneVentures, Wunala Capital, Acorn Capital, and Boman Group have invested in ImmVirx.

  • Who are ImmVirx’s competitors?

    Valo Therapeutics, Imugene, and Atara Biotherapeutics are competitors of ImmVirx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process